Clostridium difficile

The firm saw strong growth in respiratory illness assays and lead testing, which was offset by a decline in C. difficile testing.

The test, which runs on the firm's Revogene molecular diagnostics instrument, has now been launched in Canada.

Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.

Microgenics, Astute Medical, and Siemens were among the firms whose tests and/or systems were cleared by the FDA for marketing last month.

The Québec-based firm launched the test, which detects the toxin B gene of toxigenic C. diff strains directly from stool samples, in the US today.